Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study https://t.co/hV38DOAcrF #ScientiaVH
RT @PharmaFactz: 👉More information on Lytgobi: https://t.co/NBZPfcNu2Q
RT @PharmaFactz: 👉More information on Lytgobi: https://t.co/NBZPfcNu2Q
RT @PharmaFactz: 👉More information on Lytgobi: https://t.co/NBZPfcNu2Q
RT @analytics_drug: Pour Plus de détail ➡️ https://t.co/2AHQMNCOqX
Pour Plus de détail ➡️ https://t.co/2AHQMNCOqX
RT @PharmaFactz: 👉More information on Lytgobi: https://t.co/NBZPfcNu2Q
👉More information on Lytgobi: https://t.co/NBZPfcNu2Q
RT @ElizSMcKenna: Futibatinib approved for FGFR2-rearranged cholangiocarcinoma! ICYMI in @CD_AACR: Futibatinib, an Irreversible FGFR1–4 Inh…
RT @ElizSMcKenna: Futibatinib approved for FGFR2-rearranged cholangiocarcinoma! ICYMI in @CD_AACR: Futibatinib, an Irreversible FGFR1–4 Inh…
Futibatinib approved for FGFR2-rearranged cholangiocarcinoma! ICYMI in @CD_AACR: Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study https://t.co/cGovrOSTW6
RT @W_Park_MD: 9/12 #TumorBoardTuesday Mini-Tweetorial 5 👨🏫 Many FGFR inhibitors 💊Pemigatinib https://t.co/163squfYOj https://t.co/fg1Enqi…
RT @W_Park_MD: 9/12 #TumorBoardTuesday Mini-Tweetorial 5 👨🏫 Many FGFR inhibitors 💊Pemigatinib https://t.co/163squfYOj https://t.co/fg1Enqi…
RT @TumorBoardTues: 5/8 #TumorBoardTuesday Friday Case🎀 Gem/cis→stable dz for a while G2✋🏽🦶🏽neuropathy! Transition to FOLFIRI. But: 😱Re…
RT @TumorBoardTues: 6/8 #TumorBoardTuesday Friday Case🎀 Which led to @W_Park_MD’s mini-tweetorial about post-gemcitabine tx options in #CC…
RT @TumorBoardTues: 6/8 #TumorBoardTuesday Friday Case🎀 Which led to @W_Park_MD’s mini-tweetorial about post-gemcitabine tx options in #CC…
RT @TumorBoardTues: 5/8 #TumorBoardTuesday Friday Case🎀 Gem/cis→stable dz for a while G2✋🏽🦶🏽neuropathy! Transition to FOLFIRI. But: 😱Re…
6/8 #TumorBoardTuesday Friday Case🎀 Which led to @W_Park_MD’s mini-tweetorial about post-gemcitabine tx options in #CCA, guided by NGS! https://t.co/Jt7eHswJD0
5/8 #TumorBoardTuesday Friday Case🎀 Gem/cis→stable dz for a while G2✋🏽🦶🏽neuropathy! Transition to FOLFIRI. But: 😱Repeat liquid NGS + RNA analysis shows FGFR-BICC1 fusion (the MOST common fusion in #CCA)!! 🤔What to do now❓ 💡✅FGFR inhibitor! https://t
RT @W_Park_MD: 9/12 #TumorBoardTuesday Mini-Tweetorial 5 👨🏫 Many FGFR inhibitors 💊Pemigatinib https://t.co/163squfYOj https://t.co/fg1Enqi…
RT @W_Park_MD: 9/12 #TumorBoardTuesday Mini-Tweetorial 5 👨🏫 Many FGFR inhibitors 💊Pemigatinib https://t.co/163squfYOj https://t.co/fg1Enqi…
RT @W_Park_MD: 9/12 #TumorBoardTuesday Mini-Tweetorial 5 👨🏫 Many FGFR inhibitors 💊Pemigatinib https://t.co/163squfYOj https://t.co/fg1Enqi…
RT @W_Park_MD: 9/12 #TumorBoardTuesday Mini-Tweetorial 5 👨🏫 Many FGFR inhibitors 💊Pemigatinib https://t.co/163squfYOj https://t.co/fg1Enqi…
RT @W_Park_MD: 9/12 #TumorBoardTuesday Mini-Tweetorial 5 👨🏫 Many FGFR inhibitors 💊Pemigatinib https://t.co/163squfYOj https://t.co/fg1Enqi…
9/12 #TumorBoardTuesday Mini-Tweetorial 5 👨🏫 Many FGFR inhibitors 💊Pemigatinib https://t.co/163squfYOj https://t.co/fg1Enqit19 💊Infigratinib https://t.co/25AvvZqBe6 https://t.co/zXji1wVzF3 💊Derazantinib https://t.co/VwqnXBqqYl 💊Futibatinib https://t.co/G
RT @cancer_evolve: DRUG TARGETS: an irreversible pan-FGFR inhibitor (futibatinib) delivered ORR 14% in a basket study; highest response rat…
DRUG TARGETS: an irreversible pan-FGFR inhibitor (futibatinib) delivered ORR 14% in a basket study; highest response rates were in patients with FGFR fusions although responses were also seen in tumours harbouring missense mutations and amplifications. htt
From the February issue: Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors with #FGF/#FGFR aberrations: a phase I dose-expansion study by Funda Meric-Bernstam, Lipika Goyal, et al. https://t.co/2xv2FdyLer @MDAndersonNew
Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study [Research Articles] https://t.co/Qgg7sksXcU https://t.co/esBYJMVzXO
RT @DraettaG: MD Anderson Research News - Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring…
RT @DraettaG: MD Anderson Research News - Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring…
MD Anderson Research News - Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF/FGFR aberrations: a phase I dose-expansion study https://t.co/iGUuLBh0w4
Open Access UCL Research: Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF/FGFR aberrations: a phase I dose-expansion study https://t.co/PsJr8aRbvU
RT @ElizSMcKenna: Now online in @CD_AACR: Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors with #FGF/…
RT @NatRevClinOncol: In a phase I study of the FGFR1-4 TKI futibatinib in 197 pts with advanced-stage solid tumours, the ORR was 13.7% over…
RT @NatRevClinOncol: In a phase I study of the FGFR1-4 TKI futibatinib in 197 pts with advanced-stage solid tumours, the ORR was 13.7% over…
RT @NatRevClinOncol: In a phase I study of the FGFR1-4 TKI futibatinib in 197 pts with advanced-stage solid tumours, the ORR was 13.7% over…
エキパネでも皆さんお馴染みの本邦代表FGFR阻害剤フチバチニブ(TAS-120)、FGFR2点座融合等で臓器横断で奏効率25.4%って思ったより随分低い気がするな…。FIGHT-202試験のペミガチニブはORR 4割近いので、それに比べるとちょっと見劣りする。。
In a phase I study of the FGFR1-4 TKI futibatinib in 197 pts with advanced-stage solid tumours, the ORR was 13.7% overall & 25.4% in pts with FGFR2-rearranged iCCA; responses were observed in some pts with acquired resistance to a prior FGFR TKI: https
Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF/FGFR aberratio… https://t.co/RirVepnslF #hvhebron #onco
RT @ElizSMcKenna: Now online in @CD_AACR: Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors with #FGF/…
RT @ElizSMcKenna: Now online in @CD_AACR: Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors with #FGF/…
The phase 1 dose expansion trial of FGFR 1-4 inhibitor Futibatinib has been published in @CD_AACR . Anti-tumor activity is seen including in tumors with previously uncharacterized FGFR1-3 aberrations and after previous treatment with another FGFR inhibitor
RT @ElizSMcKenna: Now online in @CD_AACR: Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors with #FGF/…
RT @ElizSMcKenna: Now online in @CD_AACR: Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors with #FGF/…
RT @ElizSMcKenna: Now online in @CD_AACR: Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors with #FGF/…
Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors with #FGF/#FGFR aberrations: a phase I dose-expansion study by Funda Meric-Bernstam, Lipika Goyal, et al. https://t.co/X1BWuzoeHM. @MDAndersonNews @MGHCancerCenter http
RT @ElizSMcKenna: Now online in @CD_AACR: Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors with #FGF/…
RT @ElizSMcKenna: Now online in @CD_AACR: Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors with #FGF/…
RT @ElizSMcKenna: Now online in @CD_AACR: Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors with #FGF/…
RT @ElizSMcKenna: Now online in @CD_AACR: Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors with #FGF/…
Outstandingly promising drug
RT @ElizSMcKenna: Now online in @CD_AACR: Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors with #FGF/…
RT @ElizSMcKenna: Now online in @CD_AACR: Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors with #FGF/…
Now online in @CD_AACR: Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors with #FGF/#FGFR aberrations: a phase I dose-expansion study by Funda Meric-Bernstam, Lipika Goyal, et al. @MDAndersonNews @MGHCancerCenter https: